Jamjiro, Shaimen E.
HRN: 29-04-79 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/04/2026
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/04/2026
06/11/2026
IV
39mg
Q24
Omphalitis
Checking Final Appropriateness
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes